SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Genmab Reports Median Survival in Phase 2 Petosemtamab Combination Study

Genmab reported median survival with a petosemtamab combination in a Phase 2 study.

GENMAB

Related stories